Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRISP study in secondary progressive multiple sclerosis
ACTRN12616000178448Phase 2Terminated
- Sponsor
- Victoria University of Wellington
- Start
- May 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of clozapine and risperidone in secondary-progressive multiple sclerosis (SPMS), sponsored by Victoria University of Wellington. Started May 2016; status: terminated.
02
Drugs
clozapinerisperidone
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on ACTRN12616000178448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000178448.